+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

An antisense bcl-2 oligonucleotide alters cell proliferation, viability and programmed cell death in non-small cell lung cancer cell lines



An antisense bcl-2 oligonucleotide alters cell proliferation, viability and programmed cell death in non-small cell lung cancer cell lines



Proceedings of the American Association for Cancer Research Annual Meeting 38: 135




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 030008030

Download citation: RISBibTeXText


Related references

A bi-specific antisense bcl-2/bcl-xL oligonucleotide induces programmed cell death in four morphologically and genetically distinct non-small cell lung cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 44: 65, 2003

Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23(2): 115-127, 1999

Combinational effects of vitamin D3 and retinoic acid (all trans and 9 cis) on proliferation, differentiation, and programmed cell death in two small cell lung carcinoma cell lines. Biochemical and Biophysical Research Communications 249(3): 735-744, 1998

Induction of multiple programmed cell death pathways by IFN-b in human non-small-cell lung cancer cell lines. Experimental Cell Research 247(1): 3-41, 1999

Induction of multiple programmed cell death pathways by IFN-beta in human non-small-cell lung cancer cell lines. Experimental Cell Research 247(1): 133-141, 1999

Mechanism of interferon beta-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines. Journal of the National Cancer Institute 87(3): 206-212, 1995

Programmed cell death protein 1 and programmed death-ligand 1 are expressed on the surface of some small-cell lung cancer lines. American Journal of Cancer Research 5(4): 1553-1557, 2015

Effects of STAT3 antisense oligonucleotide on proliferation and apoptosis of non-small cell lung cancer cell line A549. Ai Zheng 26(8): 820-827, 2007

Programmed cell death protein-1/programmed death-ligand 1 blockade enhances the antitumor efficacy of adoptive cell therapy against non-small cell lung cancer. Journal of Thoracic Disease 10(12): 6711-6721, 2018

Inhibition of proliferation by L-myc antisense DNA in small cell lung cancer cell lines. Proceedings of the American Association for Cancer Research Annual Meeting 36: 410, 1995

Three cases of immune cholangitis related to antiprogrammed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer. European Journal of Cancer 115: 107-110, 2019

Prognostic Value of Red Blood Cell Distribution Width in Non-small Cell Lung Cancer Treated With Anti-programmed Cell Death-1 Antibody. In Vivo 33(1): 213-220, 2018

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 36(28): 2872-2878, 2018

The inhibition of aromatase alters the mechanical and rheological properties of non-small-cell lung cancer cell lines affecting cell migration. Biochimica et Biophysica Acta 1853(2): 328-337, 2015

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma. Diagnostic Pathology 11(1): 95, 2016